BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 14, 2005
 |  BioCentury  |  Tools & Techniques

Iressa springboard

ViroLogic Inc. thinks it can have a test on the market by next year that will identify non-small cell lung cancer patients who could benefit from marketed EGFR inhibitors. Last week, AstraZeneca plc agreed to supply more than 100 patient samples to VLGC in a move that could help keep Iressa on the market, while also enabling VLGC to develop a test that would be applicable to all EGFR inhibitors.

As part of its post-marketing requirements following accelerated approval, AstraZeneca (LSE:AZN; AZN, London, U.K.) is performing biomarker studies to identify the patients who can benefit from Iressa, an epidermal growth...

Read the full 500 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >